Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

Clinical trial NCT02047513 · COMPLETED

Trial details

NCT number: NCT02047513
Sponsor: AIO-Studien-gGmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Pancreatic Cancer Ductal Adenocarcinoma of the Pancreas

Start date: 2015-07-01
Primary completion: 2021-04-01
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.